Valere P E, Tricot R
Ann Anesthesiol Fr. 1978;19(8):727-33.
The current situation concerning the use of Streptokinase in the treatment of recent myocardial infarction does not make it possible to draw any definite conclusions with regard to its therapeutic value:--mortality would not appear to be significantly modified in the majority of series;--the occurrence rate of major complications during the acute phase is not notably altered but it seems possible that the electrocardiographic course of the necrosis is more favourable under the influence of Streptokinase when treatment is begun early. The long term course cannot be assessed. Finally, it is certain that the tolerance of Streptokinase therapy has been good in all the published series. In particular, Streptokinase does not appear to have been associated with severe haemorrhagic complications nor a higher prevalence of cardiac rupture.
目前使用链激酶治疗近期心肌梗死的情况，使得无法就其治疗价值得出任何明确结论：——在大多数系列研究中，死亡率似乎没有显著改变；——急性期主要并发症的发生率没有明显变化，但在早期开始治疗时，链激酶的影响似乎可能使坏死的心电图进程更有利。长期病程无法评估。最后，可以确定的是，在所有已发表的系列研究中，链激酶治疗的耐受性良好。特别是，链激酶似乎与严重出血并发症无关，也没有更高的心脏破裂发生率。
